Week In Review: $1.5 Billion Total In Week's China Deals

Everest Medicines of Shanghai completed a $451 million IPO in Hong Kong to develop its portfolio of eight assets in-licensed for China development. The company's stock climbed 32% in its first trading session.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.